Premium
Applicability of teicoplanin dosage adjustment guidelines for renally impaired patients over the range of 3 to 30MGKG −1
Author(s) -
Smithers Jacquelyn A.,
Thompson Gary A.,
Kenny Michael T.,
Dulworth Jacqueline K.,
Kulmala Henrik K.,
Lewis Eric W.,
Ruberg Stephen J.,
Shapiro Bruce E.,
Keane William F.,
Halstenson Charles E.
Publication year - 1992
Publication title -
biopharmaceutics and drug disposition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.419
H-Index - 58
eISSN - 1099-081X
pISSN - 0142-2782
DOI - 10.1002/bdd.2510130803
Subject(s) - medicine , teicoplanin , renal function , pharmacokinetics , urology , urine , crossover study , creatinine , placebo , alternative medicine , pathology , vancomycin , biology , bacteria , genetics , staphylococcus aureus
The pharmacokinetics of teicoplanin were investigated in 13 subjects with various degrees of renal impairment using a randomized two‐period crossover design; 11 subjects completed both periods. Doses of 3 and 30 mg kg −1 were administered as single dose, 60‐min constant rate intravenous infusions. Blood samples were obtained over 28 days and urine was collected over 48 h. Serum and urine were analyzed using a microbiological assay. As previously observed in studies conducted in renally impaired subjects, teicoplanin total and renal clearance significantly decreased with decreasing creatinine clearance ( p <0·0001). However, for these parameters, no differences between doses were observed. Dosage adjustment guidelines for renally impaired patients are usually developed using the ratio of total clearance in renally impaired patients to the total clearance in patients with normal renal function. Since no dose‐related differences existed in the relationship between teicoplanin total clearance and creatinine clearance, initial dosage adjustment guidelines for renally impaired patients developed at 3 or 30 mg kg −1 are applicable over the range of 3 to 30 mg kg −1 .